SciBase Finalizes Directed Share Issue to Castle Biosciences - An Investment of SEK 19 Million

SciBase Concludes SEK 19 Million Directed Share Issue to Castle Biosciences

On August 1, 2025, SciBase Holding AB, a pioneering company in medical technology, announced the completion of a directed share issue amounting to approximately SEK 19 million. This issue was primarily directed toward Castle Biosciences, based in the United States, and was facilitated under the authorization granted by SciBase's annual general meeting on June 13, 2024.

Details of the Directed Share Issue

The Board of Directors of SciBase approved this significant financial move, highlighting their strategy to raise capital for future growth and development. The share price in this directed issue was set at SEK 0.40 per share. Notably, Castle Biosciences' participation hinged on receiving a notification from the Swedish Inspectorate of Strategic Products (ISP) regarding the approval of the investment under the Swedish Screening of Foreign Direct Investment Act 2023560. This regulatory body subsequently confirmed that the application was processed without action.

As a result, all shares allocated in the directed issue have now been fully subscribed. The allocation of shares was officially resolved by the SciBase Board on the same day, indicating their readiness to enhance shareholder value and stabilize long-term financial health. Through this initiative, the company aims to leverage Castle Biosciences' expertise in dermatological advancements, ultimately benefiting both parties involved.

Implications on Share Capital

The directed share issue will lead to an increase of SEK 2,394,347.50 in SciBase’s share capital through the issuance of 47,886,950 new shares. This move results in a dilution effect for existing shareholders amounting to approximately 11.6% of the total shares in the company. While some shareholders may view dilution negatively, the injected capital will provide the firm with necessary resources for R&D, marketing, and other operative strategies, engaging further in the medical technology sector.

About SciBase and Its Innovations

SciBase has long been recognized for its innovation in medical technology, specializing particularly in early detection methods within dermatology. The company’s flagship product, Nevisense, incorporates cutting-edge artificial intelligence (AI) technology to improve diagnostic accuracy for skin diseases, ensuring patient welfare and minimizing healthcare costs. This partnership with Castle Biosciences could signal significant advancements in their product offerings and market reach. The collaboration showcases both firms’ commitment to healthcare innovation and improving patient outcomes.

With a strong foundational research base from the Karolinska Institutet, SciBase not only positions itself as a leader in dermatological solutions but also as a role model for integrating technology with health diagnostics. The company's continued efforts in developing tools that aid in skin disease prevention reflect its core mission of enhancing lives through technology.

Conclusion

The completion of this directed share issue encapsulates SciBase's strategic steps toward expansion and innovation in the medical technology landscape. By securing this partnership with Castle Biosciences and increasing its capital, SciBase is set to push boundaries in dermatological research and product development, potentially revolutionizing how skin diseases are diagnosed and treated. Investors will be keen to observe how this influx of capital might translate into advancements in their technology and overall market performance.

For more detailed information about SciBase’s future endeavors, their products, and corporate strategies, visit SciBase.